Data from the P&S Market Research indicated the already lucrative global animal pharmaceutical market, valued at $12,614.3 million total in 2015, will increase at a CAGAR of 7.7 percent by 2022.
By Jocelyn Aspa
Trevena, AVEO, Aralez, Miragen and Curis top the NASDAQ biotech stock list.
The biotech sector has steadily enjoyed an increase this year, in part thanks to significant advancements and in spite of the uncertainty from the White House as the proposal of a new healthcare bill holds the grip of most life science markets.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
A new preliminary research report from the Canadians for Fair Access to Medical Marijuana group shows that under current laws, medical cannabis users could face impaired driving charges through a method which doesn’t accurately test them.
The Investing News Network had the chance to speak with Titan Medical CEO about its robotic medical application and how the company looks to compete in the robotics surgery market.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.
The industry’s valuation has improved significantly, says S&P Global, but is still just $1.3 trillion — equivalent to that of Apple and Google combined. Plus five other insights from the firm’s latest report.
An EY market report indicates that the biotech industry sees growth this year in the face of political uncertainty and a pull back from capital markets.
Pharmaceutical companies work towards achieving the goal of bringing new cures or treatments to the market and improve the treatment available for patients.